Abstract
Intestinal dysbiosis plays a crucial role in the development of inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). The importance of bacterial metabolites, such as short-chain fatty acids (SCFAs), succinic and lactic acids, as well as environmental factors that affect their production in the course of IBD, remains unclear. The aim of this study was to evaluate a profile of organic acids in the stool of CD and UC patients with different disease activity. We assessed a correlation between used medications, patient’s diet, and SCFA levels. A total of 35 adult patients were included in the study. We did not observe significant differences in the levels of organic acids between the CD and UC groups, irrespective of disease activity, and a control group. However, propionic acid levels were higher in IBD patients who received trimebutine vs. those who did not (p = 0.031). Higher isobutyric acid levels were observed in patients treated with biological drugs compared with those without such treatment (p = 0.014). No significant correlations were found between organic acid levels and the frequency of dietary fiber consumption. Our results reveal a new link between medication use and organic acid levels in patients with IBD.
Highlights
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a noninfectious chronic inflammation of the gastrointestinal tract
We examined thebetween association acidsome levels and some environmental the examined association fecalbetween organicfecal acid organic levels and environmental factors that may factors may affect their production, including dietary factors and different affect theirthat production, including dietary factors and different medications used in IBD
Our results revealed a novel link between fecal levels of organic acids and acids and medications used in patients with IBD
Summary
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a noninfectious chronic inflammation of the gastrointestinal tract. It is characterized by periods of exacerbation and remission. The most common clinical symptoms in patients with CD are abdominal pain and anemia, or for those with UC, bloody diarrhea. The frequency of IBD has been increasing worldwide. According to a recent study, the global number of people with IBD has risen from 3.7 million to over 6.8 million over the past 30 years, which translates to an increase of 85.1%. The global total number of deaths has increased by 67.0% [1]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
